Thus neutrophil antagonism with CXCR2 inhibitor could potentially serve as a therapeutic approach for improving the therapeutic efficacy of immune checkpoint inhibitor treatments in lung cancer [153]. This evidence concerns the gene CXCR2 and lung carcinoma.